Impact of adjuvant endocrine therapy utilization in male patients with early breast cancer: results from a large German real-world claims data analysis.

ABSTRACT:

Background

Male breast cancer (BC) is a rare entity and represents a significant clinical challenge due to its late diagnosis and resulting poorer prognosis compared to female BC. As shown by prior studies, approximately 99% of male BC patients are hormone receptor-positive (HR +). This study aimed to evaluate the utilization and impact of adjuvant endocrine therapy (ET) in male early BC patients using a large German real-world claims dataset.

Patients and methods

Data were collected from a major German statutory health insurance provider (AOK Baden-Wuerttemberg) covering the period between January 1, 2010, and December 31, 2020. Male patients diagnosed with early BC who underwent breast surgery were included. ET use was determined by prescription records. The impact of ET o

SUBMITTER: Dannehl D 

PROVIDER: S-EPMC12705814 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature